VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Patients With Stage IV or Recurrent Endometrial Cancer

VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Patients With Stage IV or Recurrent Endometrial Cancer
Conditions:   Metastatic Endometrial Carcinoma;   Recurrent Endometrial Adenocarcinoma;   Recurrent Endometrial Carcinoma;   Recurrent Endometrial Clear Cell Adenocarcinoma;   Recurrent Endometrial Endometrioid Adenocarcinoma;   Recurrent Endometrial Mixed Cell Adenocarcinoma;   Recurrent Endometrial Serous Adenocarcinoma;   Recurrent Endometrial Undifferentiated Carcinoma;   Recurrent Uterine Corpus Carcinosarcoma;   Stage IV Uterine Corpus Cancer AJCC v7;   Stage IVA Uterine Corpus Cancer AJCC v7;   Stage IVB Uterine Corpus Cancer AJCC v7
Interventions:   Procedure: Biopsy;   Procedure: Computed Tomography;   Other: Fluorine F 18 Tetrafluoroborate;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Procedure: Planar Imaging;   Procedure: Positron Emission Tomography;   Biological: Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter;   Drug: Ruxolitinib;   Drug: Ruxolitinib Phosphate;   Procedure: Single Photon Emission Computed Tomography;   Drug: Technetium Tc-99m Sodium Pertechnetate
Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

July 19, 2022Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments